Delivery Order HHSN261201600022I-HHSN26100001

Award Date 7/1/16
Potential Completion Date 9/30/16
Potential Value $685
Ultimate Awardee
Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Pittsburgh, PA 15213, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
5
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $1,010.00 firm fixed-price delivery order awarded by the National Cancer Institute (NCI) to the IIT Research Institute (IITRI), a non-profit contract research organization. The contract is for a "Kick Off Meeting, Preclinical Pharmacokinetic & Pharmacology Evaluations of Agents Being Developed for Cancer Patients" with a performance period from July 1, 2016 to September 30, 2016. This work is being performed under NCI's Pharmacokinetic and Pharmacology Evaluations for...
Mayo Clinic is providing research and development services as the prime contractor on a $167,149.99 delivery order against the National Cancer Institute's Pharmacokinetic and Pharmacology Evaluations for Cancer Patients indefinite delivery contract. This order is for Milestone 3 of preclinical pharmacokinetic studies with selected anticancer compounds in mice, including pharmacokinetic and pharmacology evaluations of agents being developed for cancer patients. The goal is to aid development...
The Department of Health and Human Services (HHS) National Cancer Institute awarded a $67,683 firm-fixed-price delivery order contract to the University of Pittsburgh to provide analytical support and pharmacokinetic (PK) sample analysis for preclinical pharmacology studies of agents being developed for cancer patients. The contract has a period of performance from September 16, 2019 to September 15, 2024 and is part of the larger Pharmacokinetic and Pharmacology Evaluations for Cancer...
This is a firm-fixed price delivery order awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Mayo Clinic, a renowned non-profit academic medical center. The contract is for $1,603.00 and covers pre-clinical pharmacokinetic and pharmacology evaluations of cancer therapeutic agents being developed under the NCI's Experimental Therapeutics program. This work supports the transition of promising cancer treatments from the laboratory to early...
The National Cancer Institute, a component of the National Institutes of Health within the Department of Health and Human Services, awarded a $2.4 million delivery order against the Toxicology of Drugs Developed for Cancer Patients master IDIQ contract to IIT Research Institute. Under this order, IIT Research Institute will provide toxicology services to support the preclinical development of EIF4A inhibitors rocaglamide and didesmethylrocaglamide from September 2020 through September 2023 in...
This is a delivery order under the Toxicology of Drugs Developed for Cancer Patients contract vehicle, awarded by the National Cancer Institute (NCI) to Battelle Memorial Institute. The $248,269.21 cost-plus-fixed-fee contract is for a pre-clinical toxicity study to characterize the toxicity of potential anticancer compounds following multiple dose administration to rats. The contract runs from January 18, 2017 to June 30, 2018. No set-aside designation is mentioned. Battelle frequently serves...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency, to the University of Illinois. The contract is valued at $761,043.02 and is part of the larger "Toxicology of Drugs Developed for Cancer Patients" indefinite delivery/indefinite quantity (IDIQ) contract vehicle. The purpose of this award is to conduct pre-clinical toxicology studies of a drug candidate, specifically DNA methyltransferase-TdCyd, for potential use in...
This is a federal contract award made by the National Cancer Institute (NCI), a civilian agency, to the University of Pittsburgh. The contract is for the determination of LMP744 (NSC 706744) levels in human plasma and urine samples from an NCI Phase I trial. The contract has a ceiling value of $408,140.33 and a period of performance from April 1, 2017 to June 30, 2022. It is a delivery order contract under the Pharmacokinetic and Pharmacology Evaluations for Cancer Patients master IDIQ. The...
This is a Cost Plus Fixed Fee delivery order contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute to Battelle Memorial Institute, a non-profit organization and manufacturer of goods. The contract is for an exploratory toxicology study in dogs of an MCL-1 inhibitor drug being developed for cancer and other diseases. The contract has a potential value of $116,039 and a completion date of June 30, 2021. It is a task...
This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the IIT Research Institute (IITRI), a non-profit contract research organization. The $4,145 contract is for a pre-clinical toxicology study of a drug developed for cancer patients, as part of the Toxicology of Drugs Developed for Cancer Patients contract vehicle. IITRI specializes in preclinical drug development services and has...

KICK-OFF MEETING PRECLINICAL PHARMACOKINETIC & PHARMACOLOGY EVALUATIONS OF AGENTS BEING DEVELOPED FOR CANCER PATIENTS, 7/1/2016-9/30/16, HHSN261201600022I

Posted 7/1/16, 12:00 AM